RIGImmune Inc

RIGImmune Inc. is a privately held biopharmaceutical company headquartered in Farmington, Connecticut. Founded in 2020, RIGImmune employs 12 individuals and generates approximately $2.5 million in annual revenue. RIGImmune specializes in developing RNA immunotherapies designed to modulate RIG-I, a host surveillance pathway that activates the innate immune system. These therapies aim to enhance patients' natural defenses against viral diseases and cancer. Their platform technology includes complementary targeted delivery systems to ensure effective treatment. Driven by scientific innovation, RIGImmune's founders, Yale Professors Anna Marie Pyle, PhD, and Akiko Iwasaki, PhD, are renowned experts in RNA structure, design, and immunology. Their research led to the discovery of the RIG-I receptor family and the development of stem loop RNAs for selective targeting of RIG-I, paving the way for RIGImmune's groundbreaking therapies. For further details about RIGImmune's innovative solutions, please visit their website at rigimmune.com.